LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urine-Based Molecular Test Detects Bladder Cancer Quickly and Accurately

By LabMedica International staff writers
Posted on 14 Mar 2023
Print article
Image: Researchers have developed a novel urine-based test for the non-invasive detection of bladder cancer (Photo courtesy of Nonacus)
Image: Researchers have developed a novel urine-based test for the non-invasive detection of bladder cancer (Photo courtesy of Nonacus)

Flexible cystoscopy, an invasive procedure involving the insertion of a camera into the bladder, is currently the main technique used to identify bladder cancer tumors. However, this process can be uncomfortable and expensive for patients, and the majority of these cystoscopies result in no abnormalities or malignancies being detected. Now, a new urine-based molecular test can rapidly and precisely detect bladder cancer, thereby streamlining diagnosis and minimizing the necessity for invasive procedures like cystoscopies.

A collaboration between the University of Birmingham (Birmingham, UK) researchers and liquid biopsy cancer detection and screening company Nonacus (Birmingham, UK) has resulted in a novel test for the non-invasive detection of bladder cancer. The GALEAS Bladder from Nonacus is a non-invasive, urine-based diagnostic test designed to provide a sample-to-report molecular triage for patients exhibiting symptoms of hematuria (blood in urine). The urine-based molecular biomarker provides a highly sensitive test that enables the rapid and precise detection of bladder cancer, thus enhancing diagnosis and eliminating the need for invasive cystoscopies.

The test combines highly sensitive liquid biopsy technology with a panel of biomarkers to detect the presence of bladder cancer by locating DNA from tumor cells in urine. The biomarker panel has been validated by the researchers in more than 600 patient samples from three UK clinical cohorts. Their analysis has shown the test to have a high diagnostic accuracy (sensitivity >90%, specificity >85%) across all grades and stages of bladder cancer. The test could potentially work across the entire bladder cancer patient pathway, reducing dependence on invasive cystoscopy and expensive imaging for non-muscle-invasive bladder cancer surveillance and minimal residual disease monitoring, as well as triage for hematuria.

“We are very excited to launch GALEAS Bladder,” said Chis Sale, CEO of Nonacus. “We are striving to develop a suite of meaningful non-invasive tools that can have real impact on the diagnosis and treatment of patients with suspected cancer. GALEAS Bladder represents the first in this pipeline, helping to improve patients' lives and reducing the burden of cystoscopy on overstretched clinics.”

Related Links:
University of Birmingham 
Nonacus

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more